As the coronavirus surges across the globe, diagnostic testing comes into its own, as researchers unite to confront, delay and stop its spread. In the absence of either proven effective therapy or a vaccine, diagnostic testing becomes a valuable tool.
Take a look at our day-by-day updates covering the latest on therapeutics and vaccines for COVID-19, from new partnerships to clinical trials..
Catch up on February’s industry headlines, including an MRSA breakthrough, a patent lawsuit, and the latest updates on the coronavirus outbreak and its impact on the biotechnology industry worldwide.
Take a look at the industry headlines from the last 2 months, including the FDA…
Take a look at this month’s industry headlines including results for Takeda’s dengue vaccine, approvals for Merck’s Ebola vaccine and the advent of a siderophore antibiotic – the first of this kind.
The US FDA has approved cefiderocol (Fetroja), a siderophore cephalosporin that inhibits bacterial cell wall synthesis. Fetroja is the first approved antibiotic that functions as a siderophore.
Take a look at this month’s industry headlines including US FDA approvals for XOFLUZATM and…
Take a look at this month’s industry headlines including FDA warnings over hepatitis C drugs in patients with liver injury, a new infectious diseases strategy for the UK and priority review for Merck’s Ebola vaccine.
US FDA approvals for antibiotic Xenleta™ and tuberculosis drug Pretomanid: August’s industry headlines
Take a look at this month’s industry headlines including US FDA approvals for two drugs – Xenleta™ and Pretomanid – in addition to an EMA decision for Zerbaxa®, partnerships for vaccine development and results on Ebola therapeutics.
US FDA approves RECARBRIO™ for complicated UTIs and complicated intra-abdominal infections: July’s industry headlines
Take a look at this month’s industry headlines including a US FDA approval for RECARBRIO™, positive results for XOFLUZA in children and new ACIP recommendations.